Literature DB >> 2862652

Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.

R C Smith, R Baumgartner, A Shvartsburd, G K Ravichandran, G Vroulis, M Mauldin.   

Abstract

The relative utility of steady-state (SS), plasma (Pl), and red blood cell (RBC) haloperidol levels for predicting clinical response was evaluated in a fixed-dose study in schizophrenic inpatients. There were significant curvilinear relationships between the decrease in BPRS Psychosis Factor Scores by day 24 of haloperidol treatment and both Pl (R2 = 0.34) and RBC (R2 = 0.38) haloperidol levels. Although SS RBC haloperidol levels consistently showed a slightly stronger relationship to clinical response than Pl levels in several comparisons, the differences in R2s between Pl and RBC haloperidol were not statistically significant. Ninety percent confidence intervals for the blood level ranges associated with optimal clinical response in our sample of patients were: 6.5-16.5 ng/ml Pl haloperidol and 2.2-6.8 ng/ml RBC haloperidol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862652     DOI: 10.1007/bf00429663

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  On the methods and theory of reliability.

Authors:  J J Bartko; W T Carpenter
Journal:  J Nerv Ment Dis       Date:  1976-11       Impact factor: 2.254

2.  Haloperidol plasma levels and clinical response: basic concepts and clinical data.

Authors:  J M Davis; S E Ericksen; S Hurt; S S Chang; J I Javaid; H Dekirmenjian; R Casper
Journal:  Psychopharmacol Bull       Date:  1985

3.  Akathisia with haloperidol and thiothixene.

Authors:  T Van Putten; P R May; S R Marder
Journal:  Psychopharmacol Bull       Date:  1984

4.  Plasma and red cell levels of thioridazine and clinical response in schizophrenia.

Authors:  R C Smith; R Baumgartner; G K Ravichandran; A Shvartsburd; J C Schoolar; P Allen; R Johnson
Journal:  Psychiatry Res       Date:  1984-08       Impact factor: 3.222

5.  Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.

Authors:  D L Garver; H Dekirmenjian; J M Davis; R Casper; S Ericksen
Journal:  Am J Psychiatry       Date:  1977-03       Impact factor: 18.112

6.  Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.

Authors:  A Shvartsburd; V Nwokeafor; R C Smith
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Clinical response and plasma haloperidol levels in schizophrenia.

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Relationship of serum haloperidol levels to clinical response in schizophrenic patients.

Authors:  J R Magliozzi; L E Hollister; K V Arnold; G M Earle
Journal:  Am J Psychiatry       Date:  1981-03       Impact factor: 18.112

9.  Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia.

Authors:  R Casper; D L Garver; H Dekirmenjian; S Chang; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1980-03

10.  Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.

Authors:  R C Smith; R Baumgartner; C H Misra; M Mauldin; A Shvartsburd; B T Ho; C DeJohn
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.